advertisement
Abstract #12262 Published in IGR 7-2
The efficacy of bimatoprost 0.03% monotherapy in patients previously using topical β-blocker monotherapy for the treatment of glaucoma or ocular hypertension
Quinones R; Earl MLAdvances in Therapy 2004; 21: 370-379
In an open-label 12-week study, the safety and efficacy of bimatoprost 0.03% was evaluated in 55 patients with open-angle glaucoma or ocular hypertension inadequately controlled by topical β-blocker monotherapy. Patients discontinued their topical β-blocker therapy at the baseline visit and began bimatoprost monotherapy that evening. Study visits were at 6 and 12 weeks postbaseline. Bimatoprost reduced intraocular pressure (IOP) 4.5 mmHg (21.5%; P < .001) from baseline at week 6 and 4.2 mmHg (19.6%; P < .001) at week 12. Patients were more likely to achieve low target pressures with bimatoprost than with topical β-blockers. Conjunctival hyperemia was the most commonly reported adverse event. The findings from this study indicate bimatoprost monotherapy provides a substantially greater IOP reduction than topical β-blocker therapy and allows more patients to achieve a low target pressure. Bimatoprost is an effective alternative to topical β-blockers for the treatment of glaucoma and ocular hypertension.
Dr. R. Quinone, Arbor Center for Eye Care, 2640 183rd Street, Homewood, IL 60430, USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
